Institut Català d'Oncologia

Sep 9, 2024 | aacrjournals.org | Byoung Chul Cho |Byoung Chul |Institut Català d'Oncologia |Hospitalet de Llobregat

Background: ETOP 10-16 BOOSTER study was a randomised phase II trial of osimertinib and bevacizumab versus osimertinib in patients with an acquired EGFR T790M mutation. The mechanisms of acquired resistance to osimertinib and bevacizumab have not been described previously. Methods: Next generation sequencing (Guardant360®) was conducted in serial plasma samples. The association between ctDNA and efficacy outcomes was explored and molecular alterations at progression were described.

Jul 30, 2024 | aacrjournals.org | Institut Català d'Oncologia

This content is only available via PDF. This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License .

Nov 27, 2023 | onlinelibrary.wiley.com | Sandra Castaño-Díez |Helena Pomares |Institut Català d'Oncologia |Hospitalet de Llobregat

CONFLICT OF INTEREST STATEMENT J.E.: consultancy-honoraria (AbbVie, Novartis, Astellas Pharma, Jazz Pharmaceuticals, BMS-Celgene, Pfizer and Daichii-Sankyo), research grants (Novartis and Jazz Pharmaceuticals); M.D.B.: consultant or advisory role, travel grants or speaker (Bristol Myers Squibb, AbbVie, Astellas Pharma, Jazz Pharmaceuticals, Takeda Pharmaceuticals, Novartis).

Jul 25, 2023 | aacrjournals.org | Institut Català d'Oncologia |Hospitalet de Llobregat |Ciruelos Gil |Margeli Vila

Citation Javier PascualMiguel Gil-GilPaula ProszekChristoph ZielinskiAlistair ReayManuel Ruiz-BorregoRosalind CuttsEva M. Ciruelos GilAndrew FeberMontserrat Muñoz-MateuClaire SwiftBegoña BermejoJesus HerranzMireia Margeli VilaAntonio AntónZsuzsanna KahanTibor CsösziYuan LiuDaniel Fernandez GarciaIsaac Garcia-MurillasMichael HubankNicholas C.

Jul 13, 2023 | aacrjournals.org | Institut Català d'Oncologia |L'hospitalet de Llobregat |Jose Manuel |Hospitalet de Llobregat

Purpose: Current diagnostic methods for endometrial cancer lack specificity, leading to many women undergoing invasive procedures. The aim of this study was to evaluate somatic mutations in urine to accurately discriminate endometrial cancer patients from controls. Experimental Design: Overall, 72 samples were analyzed using next-generation sequencing with molecular identifiers targeting 47 genes.